Publications by authors named "Jaegon Ah"
Mesenchymal stem cell (MSC) therapy has been actively applied in veterinary regenerative medicine to treat various canine and feline diseases. With increasing emphasis on safe cell-based therapies, evaluations of their tumorigenic potential are in great demand. However, a direct confirmation of whether tumors originate from stem cells or host cells is not easily achievable.
View Article and Find Full Text PDFArticle Synopsis
- Meningoencephalomyelitis of unknown etiology (MUE) is a non-infectious inflammatory brain condition in dogs, linked to abnormal autoimmune responses, and this study reviews the effects of different immunosuppressants on survival and clinical outcomes.
- A total of 82 dogs were assessed, revealing varying median survival times based on the treatment: leflunomide had the longest (1035 days), while a combination therapy showed the shortest (132 days), with no significant difference in adverse event rates except for moderate to severe anemia in one group.
- The findings suggest that the type of immunosuppressant impacts survival and response, particularly highlighting leflunomide as effective, but the study calls for